Get to Know MgShell: A Controlled Drug Release Device for Chronic Eye Treatment
Get to Know MgShell: A Controlled Drug Release Device for Chronic Eye Treatment
MgShell’s i3D is a magnesium-based drug delivery system that gradually releases medication into the eye over several months with just a single injection, reducing the number of treatments by up to 66%.
The company has already surpassed its minimum investment goal, and as we enter the final days of the campaign, we invite doctors, researchers, investors, and healthcare enthusiasts to join us for an exclusive deep dive into this innovative drug-delivery device and its potential to revolutionize chronic retinal disease treatment.
Explore the details: https://capitalcell.com/en/campaign/mgshell/
What will we cover in these sessions?
What is MgShell?
Discover the team behind MgShell, their mission, current progress, and future plans.
Why is this project so relevant?
For this final webinar, MgShell has invited two industry leaders to share their insights:
Andrea Giani – Lead Investor in the current fundraising campaign and former Global Head of Medicine for Retinal Health at Boehringer Ingelheim. With over six years of experience at Boehringer Ingelheim, including three years leading retinal health, Andrea has held pivotal roles such as Senior Global Clinical Program Leader for Retinal Health. His extensive expertise will offer insights into how MgShell aligns with the broader vision for advancing eye care.
Marco Gullà – Investment associate at HTH, an italian VC fund backed by the Zambon family. Marco follows MgShell as a referral for Italian Angels for Biotech, an angel investment club based in Milan that has already invested in MgShell and is doubling down in this seed round.
Q&A Session
Get answers to your questions about Capital Cell, how it works, and how you can be part of this journey.
Spread the Word
Share this webinar with your network to help shape the future of ophthalmic care. See you there!